Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 20Leucovorin 18Oxaliplatin 11Irinotecan 10Capecitabine 6Bevacizumab 5Cetuximab 4Levamisole 3Celecoxib 3cediranib 2Watchful Waiting 2Tegafur 2Surveys and Questionnaires 2Psychiatric Rehabilitation 2Folfox protocol 2Counseling 2Cisplatin 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1regorafenib 1pertuzumab 1olaparib 1mercaptoundecahydrododecaborate 1gevokizumab 1eniluracil 1cemiplimab 1brivanib 1alpha-Tocopherol 1Vitamin E 1Uracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Colonic Neoplasms × brivanib × Clear all
NCT00640471 2023-08-04

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Canadian Cancer Trials Group

Phase 3 Completed
750 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡